Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Gross Margin (2016 - 2025)

Ani Pharmaceuticals' Gross Margin history spans 14 years, with the latest figure at 59.42% for Q4 2025.

  • For Q4 2025, Gross Margin rose 154.0% year-over-year to 59.42%; the TTM value through Dec 2025 reached 61.36%, up 209.0%, while the annual FY2025 figure was 61.36%, 209.0% up from the prior year.
  • Gross Margin for Q4 2025 was 59.42% at Ani Pharmaceuticals, up from 59.01% in the prior quarter.
  • Across five years, Gross Margin topped out at 64.7% in Q2 2025 and bottomed at 78.44% in Q1 2021.
  • The 5-year median for Gross Margin is 59.21% (2025), against an average of 51.48%.
  • The largest annual shift saw Gross Margin tumbled -13463bps in 2021 before it surged 12529bps in 2022.
  • A 5-year view of Gross Margin shows it stood at 44.36% in 2021, then soared by 39bps to 61.45% in 2022, then fell by -3bps to 59.42% in 2023, then decreased by -3bps to 57.87% in 2024, then increased by 3bps to 59.42% in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Gross Margin are 59.42% (Q4 2025), 59.01% (Q3 2025), and 64.7% (Q2 2025).